Portola Pharmaceuticals, Inc. Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers
Published: Oct 25, 2013
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that patient enrollment has begun in its PRT2070 Phase 1/2 proof-of-concept clinical study. PRT2070 is a novel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor being developed as a treatment for hematologic cancers, including for those patients who have progressive or relapsed disease, genetically-defined subtypes or acquired mutations.
Help employers find you! Check out all the jobs and post your resume.